Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescein Mapping in Patients Undergoing Vulvectomy for Extramammary Paget's Disease
NCT06873815Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorescein sodium 10% injection in extramammary Paget's disease (EMPD), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of positive pathologic surgical margin status at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
fluorescein sodium 10% injection
03
Conditions
extramammary Paget's disease (EMPD)
Beyond the preview
Go deeper on NCT06873815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873815.